Combination treatment for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. The treatments include a targeted therapy pill, a procedure that cuts off blood supply to the tumor, and radiation, plus an immunotherapy drug that helps your immune system fight the cancer. This approach aims to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with liver cancer that is confirmed by biopsy or imaging.
- Your liver cancer is at a stage where surgery is not possible, and your tumor is larger than 5 cm with up to 3 tumors.
- You have not had any prior treatment for this stage of your liver cancer (except for a stent to open a blocked bile duct).
- Your liver function is good (Child-Pugh score A or B) and you are physically active (ECOG score 0 or 1).
- Your blood counts, kidney, and liver function meet certain minimum levels (detailed by the study team).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for advanced liver cancer that has stopped responding to earlier therapy. It combines the targeted drug donafenib with immunotherapy and local treatments, which may help control the tumor better than the previous treatments.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This study looks back at patients who received a combination of donafenib (a targeted pill), immunotherapy (a medicine that helps your immune system fight cancer), and a liver-directed procedure (TACE or HAIC) as their first treatment for liver cancer that can't be surgically removed. The goal is to check how well this combination works and how safe it is.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed therapy given before surgery to shrink tumors in people with early-stage liver cancer that can be removed. The goal is to make surgery more successful and improve outcomes.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.